Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab in Recurrent Stage IV High Risk Neuroblastoma
NCT04412408Phase 1Unknown
- Start
- Sep 2020
- Primary completion
- Dec 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of sintilimab in neuroblastoma. Primary endpoint: Tumor Response at 2 years. Status: unknown.
02
Drugs
sintilimab
03
Conditions
neuroblastoma
Beyond the preview
Go deeper on NCT04412408.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04412408.